Published in Eur J Neurosci on July 01, 1996
Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry (2005) 1.69
Mechanisms and targets of deep brain stimulation in movement disorders. Neurotherapeutics (2008) 1.42
Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial. Parkinsonism Relat Disord (2011) 1.11
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale. J Parkinsons Dis (2012) 0.97
Mechanisms of deep brain stimulation. J Neurophysiol (2015) 0.93
Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. J Neurol (2008) 0.89
Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol (2010) 0.88
Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum. Eur J Neurosci (2008) 0.87
Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture. J Neurochem (2013) 0.86
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains. BMC Neurosci (2013) 0.84
Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. Exp Brain Res (2005) 0.83
Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease. Br J Pharmacol (2010) 0.83
Patterns of Cell Activity in the Subthalamic Region Associated with the Neuroprotective Action of Near-Infrared Light Treatment in MPTP-Treated Mice. Parkinsons Dis (2012) 0.83
Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease. Br J Pharmacol (2012) 0.80
Activity-dependent regulation of NMDA receptors in substantia nigra dopaminergic neurones. J Physiol (2013) 0.79
What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus? J Neural Transm (Vienna) (2010) 0.79
Subthalamic Nucleus Deep Brain Stimulation Employs TrkB Signaling for Neuroprotection and Functional Restoration. J Neurosci (2017) 0.75
STN-DBS is neuroprotective in the A53T α-synuclein Parkinson's disease rat model. Ann Neurol (2017) 0.75
The Hyperpolarization-Activated Current Determines Synaptic Excitability, Calcium Activity and Specific Viability of Substantia Nigra Dopaminergic Neurons. Front Cell Neurosci (2017) 0.75
Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med (1998) 4.72
Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg (1996) 3.37
Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 3.06
Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol (2001) 2.45
The impact on Parkinson's disease of electrical parameter settings in STN stimulation. Neurology (2002) 2.14
Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 1.88
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
The impact of deep brain stimulation on executive function in Parkinson's disease. Brain (2000) 1.74
Acute and long-term effects of subthalamic nucleus stimulation in Parkinson's disease. Stereotact Funct Neurosurg (1994) 1.66
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol (1999) 1.57
Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain (1998) 1.56
Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol (1997) 1.48
The core assessment program for intracerebral transplantation. Mov Disord (1995) 1.47
Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord (1998) 1.47
Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci Lett (1995) 1.43
Inhibition of levodopa effects by internal pallidal stimulation. Mov Disord (1998) 1.42
Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. Neuroscience (2000) 1.41
[Effects of the stimulation of the subthalamic nucleus in Parkinson disease]. Rev Neurol (Paris) (1993) 1.39
Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord (1995) 1.28
Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord (2001) 1.27
Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease. Eur Respir J (1992) 1.24
Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol (1998) 1.23
Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. AJNR Am J Neuroradiol (1995) 1.22
Deep brain stimulation in the treatment of severe dystonia. J Neurol (2001) 1.19
Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov Disord (1998) 1.17
Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry (1989) 1.16
Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: methodologic aspects and clinical criteria. Neurology (2000) 1.16
EGF receptor amplification and expression in human brain tumours. Eur J Cancer (1992) 1.12
Stimulation of the ventral intermediate thalamic nucleus in tremor dominated Parkinson's disease and essential tremor. Acta Neurochir (Wien) (1995) 1.11
Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov Disord (1996) 1.08
Effect of bilateral stimulation of the subthalamic nucleus on parkinsonian voice. Brain Lang (2001) 1.08
Effect of stimulation of the subthalamic nucleus on oral control of patients with parkinsonism. J Neurol Neurosurg Psychiatry (1999) 1.07
Contribution of dynamic contrast MR imaging to the differentiation between dural metastasis and meningioma. Neuroradiology (2004) 1.06
Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. Lancet (1997) 1.05
Deep brain stimulation of the corpus luysi (subthalamic nucleus) and other targets in Parkinson's disease. Extension to new indications such as dystonia and epilepsy. J Neurol (2001) 1.05
From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain (1999) 1.05
Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res (2001) 1.05
Subthalamic stimulation for Parkinson's disease. Arch Med Res (2000) 1.04
Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet (1997) 1.03
Thalamic stimulation and suppression of parkinsonian tremor. Evidence of a cerebellar deactivation using positron emission tomography. Brain (1993) 1.03
Functional MRI of the human brain: predominance of signals from extracerebral veins. Neuroreport (1994) 1.01
Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. Exp Neurol (2006) 1.00
Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease. J Neurol (1999) 0.98
Changes in the firing pattern of globus pallidus neurons after the degeneration of nigrostriatal pathway are mediated by the subthalamic nucleus in the rat. Eur J Neurosci (2000) 0.98
Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology (2002) 0.98
[Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease]. Rev Neurol (Paris) (1990) 0.98
Gait is associated with an increase in tonic firing of the sub-cuneiform nucleus neurons. Neuroscience (2008) 0.98
Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons. Exp Brain Res (1995) 0.97
Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. Neurology (2000) 0.97
Simultaneous recording of spontaneous activities and nociceptive responses from neurons in the pars compacta of substantia nigra and in the lateral habenula. Eur J Neurosci (1996) 0.96
Impact of deep brain stimulation on upper limb akinesia in Parkinson's disease. Ann Neurol (1999) 0.96
Long-term effects of chronic stimulation of the ventral intermediate thalamic nucleus in different types of tremor. Adv Neurol (1993) 0.96
Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol (2002) 0.95
Gradient expression of Cdx along the rat intestine throughout postnatal development. FEBS Lett (1992) 0.95
Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer (1994) 0.95
Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death. Proc Natl Acad Sci U S A (1991) 0.94
Side-effects of subthalamic stimulation in Parkinson's disease: clinical evolution and predictive factors. Eur J Neurol (2006) 0.94
Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal activity of the pedunculopontine nucleus, which is reversed by the lesion of the subthalamic nucleus in the rat. Eur J Neurosci (2001) 0.94
Future prospects of brain stimulation. Neurol Res (2000) 0.92
Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. J Neurol Neurosurg Psychiatry (1999) 0.92
The cingulate hidden hand. J Neurol Neurosurg Psychiatry (2001) 0.92
Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice. Cancer Res (1991) 0.91
Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease. Neurology (2000) 0.91
Deep brain stimulation for Parkinson's disease. Adv Neurol (2001) 0.90
Evidence for dopamine D2 receptor mRNA expression by striatal astrocytes in culture: in situ hybridization and polymerase chain reaction studies. Brain Res Mol Brain Res (1994) 0.89
Muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression. Hum Gene Ther (2000) 0.88
High-frequency stimulation of the subthalamic nucleus suppresses absence seizures in the rat: comparison with neurotoxic lesions. Epilepsy Res (1998) 0.87
Chronic subthalamic nucleus stimulation and striatal D2 dopamine receptors in Parkinson's disease--A [(11)C]-raclopride PET study. J Neurol (2003) 0.87
Extracellular toxicity of 6-hydroxydopamine on PC12 cells. Neurosci Lett (2000) 0.87
[A pneumatosis cystoides coli revealed by a pseudo-obstruction]. Ann Chir (2003) 0.87
Surgery in severe factor XIII deficiency: report of a case of epilepsy neurosurgery and review. Haemophilia (2003) 0.86
Effect of bilateral deep-brain stimulation on oral control of patients with parkinsonism. Eur Neurol (2000) 0.86
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on? Br J Neurosurg (2004) 0.86
Deep brain pallidal stimulation for movement disorders in neuroacanthocytosis. Neurology (2007) 0.86
Stereotaxic cytology of brain tumors. Review of an eight-year experience. Acta Cytol (1988) 0.86
Impairment of muscular metabolism in chronic respiratory failure. A human 31P MRS study. NMR Biomed (1991) 0.86
Dyskinesias and the subthalamic nucleus. Ann Neurol (2000) 0.85
Levodopa-inhibiting effect of pallidal surgery. Ann Neurol (1997) 0.85
Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat. Synapse (2001) 0.85
Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway. Eur J Neurosci (2001) 0.85
Intensity-dependent nociceptive responses from presumed dopaminergic neurons of the substantia nigra, pars compacta in the rat and their modification by lateral habenula inputs. Brain Res (1990) 0.85